current page

Newsroom 2017

September 28, 2017

Terumo Opens a New Innovation Center in Southern California

TOKYO, JAPAN – September 28, 2017 – Terumo Corporation (TSE: 4543) announced today that its new Innovation Center of its neurovascular and endovascular intervention businesses has opened on September 25th in California, United States.

The facility consolidates Terumo's Neurovascular Division's finance and administrative functions, global marketing and sales activities, research and development center and manufacturing, including a state-of-the-art neuroradiology imaging lab. The area of the complex is nearly doubled and is expected to support its business growth in the rapidly growing neurovascular market.

The Neurovascular Division has been developing some endovascular products for Terumo Interventional Systems Division by leveraging its resources and technologies. The opening of the new Innovation Center accelerates development of therapeutic devices with the aim of launching the products globally.

As a global corporation with unique excellence, Terumo aims to become a top brand trusted in medical settings all over the world through providing “Total Quality”: high quality in all aspect of product, supply and service.

About the Innovation Center

Location Aliso Viejo, California, United States
Business Development, manufacture, and sale of neurovascular/endovascular intervention
Products Embolization coils, stents for neurovascular, balloon catheters, embolization beads, and many other related products
Opening September, 2017
Site area 205,000 square feet
Employees More than 800

About Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with over $5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.

(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.

 

Return to page top